[PP.31.10] ENDOTHELIAL CELL GROWTH SUPPLEMENT IMPROVES CARDIAC FUNCTION FOLLOWING MOUSE MYOCARDIAL INFARCTION

2016 ◽  
Vol 34 ◽  
pp. e316-e317
Author(s):  
X. Fan ◽  
H. Shi ◽  
C.A. Drummond ◽  
J. Xie ◽  
S. Haller ◽  
...  
1992 ◽  
Vol 67 (06) ◽  
pp. 718-723 ◽  
Author(s):  
Allison J Minter ◽  
Joan Dawes ◽  
Colin N Chesterman

SummaryHeparin in combination with endothelial cell growth factor (ECGF) affects physiological responses and growth of human umbilical vein endothelial cells (HUVEC). We have examined the effect of heparin, crude ECGF (endothelial cell growth supplement [ECGS]), or both on the basal and thrombin challenged output of metabolites by HUVEC. The supernatant and/or cell lysate was assayed for released prostacyclin, von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor and thrombospondin. Heparin modified release of all these metabolites when in combination with ECGS, and in general these responses were the opposite of those generated by inflammatory mediators such as interleukin-1. It has been postulated that heparin acts by potentiating the effect of ECGF, but heparin inhibited thrombospondin release and enhanced that of von Willebrand factor in the absence of ECGS, while ECGS alone inhibited release of plasminogen activator inhibitor. Thus, under our experimental conditions it would appear that heparin and crude ECGF can affect HUVEC independently of one another.


1995 ◽  
Vol 79 (1) ◽  
pp. 141-145
Author(s):  
Şükran Şahin (Özgün) ◽  
Tevfik Akoǧlu ◽  
Roger Lawrence ◽  
Leyla Semiha Şen

2012 ◽  
Vol 159 (3) ◽  
pp. 235-237 ◽  
Author(s):  
Małgorzata Pyda ◽  
Katarzyna Korybalska ◽  
Stefan Grajek ◽  
Maciej Lesiak ◽  
Krzysztof Książek ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document